NCT07779863 · NOT YET RECRUITING

Acupressure as Long-term Intervention to Slow the Progression of Early/Mild Alzheimer's Disease

This trial tests whether a structured acupressure routine, given three times a week for a year by trained caregivers, can slow cognitive decline in older adults with early or mild Alzheimer's disease. It compares a fuller acupressure protocol against a minimal-touch control, tracking cognitive scores and blood biomarkers. It's a non-drug study, not yet proven effective.

You may qualify if

  • have at least one of the following abnormal plasma amyloid and tau levels: Aβ42/Aβ40 ratio ≤ 0.17, p-tau217 > 0.15 pg/ml, or/and p-tau181 > 3.3 pg/ml
  • have mild neurocognitive disorder with the Montreal Cognitive Assessment, Hong Kong version (HK-MoCA) in classifying mild neurocognitive disorder, in which mild neurocognitive disorder is defined as those whose HK-MoCA score falls between the 16th and 2nd percentile of his/her peers adjusted for age and education

You're excluded if

  • show moderate-to-severe dementia, as evidenced by a HK-MoCA score falling below the 2nd percentile of his/her peers adjusted for age and education
  • cannot proficiently communicate due to language function impairment
  • have severe skin lesions on acupressure areas
  • had a surgery on the head or neck
  • have a medical condition that is a contraindication for acupressure.

The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.

Eligibility criteria as of 2026-08-24

View full record on ClinicalTrials.gov

All APOE4 clinical trials